Literature DB >> 2160292

Alpha 2-adrenoreceptor status in obsessive-compulsive disorder.

M A Lee1, O G Cameron, G N Gurguis, D Glitz, C B Smith, M Hariharan, J L Abelson, G C Curtis.   

Abstract

Ten patients with obsessive-compulsive disorder (OCD) and 13 normal control subjects received intravenous infusions of 2 X 10(-6) g/kg of clonidine and normal saline on separate days. Responses to the drug relating to plasma growth hormone (GH), 3-methoxy-4-hydroxyphenylglycol (MHPG), heart rate, blood pressure, and several symptoms were determined. Additionally, platelet alpha 2-adrenoreceptor binding was measured in most of the subjects. GH, MHPG, blood pressure, and heart rate responses to clonidine did not differ between groups. As expected, patients reported more symptoms than normal subjects, and clonidine was sedating for both groups. Patients did not differ from normal subjects in the symptom response to clonidine. The maximum number of binding sites (Bmax) for tritiated clonidine was significantly greater in OCD patients than in normals. This pattern of alpha 2-adrenoreceptor status is different than the patterns in major depression and panic anxiety.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2160292     DOI: 10.1016/0006-3223(90)90045-4

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  3 in total

1.  Pentagastrin has panic-inducing properties in obsessive compulsive disorder.

Authors:  A S de Leeuw; J A Den Boer; B R Slaap; H G Westenberg
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

2.  Adenylate-cyclase activity in platelets of patients with obsessive-compulsive disorder.

Authors:  D Marazziti; S Baroni; L Palego; I Masala; G Consoli; M Catena Dell'osso; G Giannaccini; A Lucacchini
Journal:  Neuropsychiatr Dis Treat       Date:  2009-07-02       Impact factor: 2.570

3.  Multiple endocrine responses to clonidine in obsessive compulsive dissorder.

Authors:  S Khanna; P L Reddy; M N Subhash; B S Rama Rao; S M Channabasavanna
Journal:  Indian J Psychiatry       Date:  1992-07       Impact factor: 1.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.